Medivir Capital Markets Meeting on 23 February 2017

Stockholm, Sweden — Medivir AB (OMX: MVIR ) today announces that a Capital Markets Meeting will be arranged for investors, analysts and journalists, on Thursday 23 February, at 2pm - 4pm CEST, in Stockholm. 

CEO Niklas Prager and the management team will present a summary of the company’s strategy, platforms and projects and finances after the transformation of the company in 2016. After the presentation there will be a break-out session on the presented projects.

Time: Thursday 23 February, at 2pm - 4pm CEST
Venue:
IVAs Conference Center, Grev Turegatan 16, Stockholm
Invitation for: Institutional investors, analysts and media

The event will also be available after the meeting through Medivir’s website; www.medivir.com

Registration for investors, analysts and journalists
To participate, please register at; http://www.financialhearings.com/event/10014 , no later than 20 February .

For further information, please contact:
Ola Burmark, CFO, mobile: +46 725 480 580.

About Medivir
Medivir develops innovative pharmaceutical products for the treatment of cancer. The company specialises in protease inhibitor research and nucleotide/nucleoside science and conducts research in all stages of the drug development process, from original idea to clinical phase III studies. Its development work is done both in-house and through partnerships.

Tags:

About Us

Medivir develops innovative pharmaceuticals for the treatment of cancer. The company specializes within protease inhibitor research and nucleotide/nucleoside science.The research is conducted in all phases of pharmaceutical development, from idea to clinical phase III studies. The development work is conducted both in-house and through partnerships.Medivir is listed on the Nasdaq Stockholm Mid Cap List.

Subscribe

Documents & Links